Saturday, June 14, 2008

Is Your Great Idea A Real Business?

No matter how often you scrub him, Sam, your 90-pound Golden Retriever, still stinks.
Then it hits you: dog cologne! You fire up a Web search and learn that, every year, 50 million U.S. dog owners collectively spend $43 billion on their pooches. Sam can't be the only smelly one of the bunch; your idea can't miss. You even have a name for it: Furry Fragrances. Or maybe Eau de Puppe.
We've all been there: drinking our morning coffee, reading the business section, washing our dogs, when--Bam!--an idea for a new gizmo or service that's going to change the world comes crashing home. But before you liquidate your 401(k) for startup capital, step back and figure out whether your "great idea" truly translates into a money-making venture.

The first question you should ask: Do you have a compelling value proposition? This point is forever worth repeating: Great ideas are only great business ideas if you can convince people to pay for your product or service at a price above what it costs you to deliver it. Just because you think the world needs new canine cologne doesn't mean anyone else agrees--or if they do, that they would be willing to pay enough to cover your electric bill.


You don't need a 90-page business plan to convey a value proposition. In fact, you should be able to communicate it in a few sentences. If you can't figure out why your product is great, your customers probably can't, either.
Another common mistake that budding entrepreneurs make is "overestimating their originality," says Toby Stuart, a professor of entrepreneurial management at the Harvard Business School. In other words: If you've thought of it, chances are someone else has, too.


Next question: Is there a viable market for your new product or service? Professional investors (like venture capitalists) don't want to write checks to launch companies with limited growth potential, even if they'll likely be profitable. And never count on creating a new market from scratch--chances are there's a reason it doesn't exist.
On the flip side, beware the temptation to grab for a small slice of a massive pie. That $43 billion in pet supplies may sound juicy, but that doesn't mean the dollars devoted to doggie perfume are large enough to nourish a standalone business. Rather than trying to capture 1% to 2% of a giant global market, startups should aim to capture 25% to 40% of a niche market, advises John De Puy, chief executive of Oaktree Ventures, a San Diego-based venture capital firm. "Define and dominate," he says. "That's the secret sauce."
Before you can dominate, you have to cover your development costs. "Most companies that fail do so because they are lacking capital," says De Puy. The key here is honesty: However much you think you need to bring your product to market, figure in a healthy cushion. Add more for tech-heavy products that may--read: will--need extra months of tweaking. If you can't scare up enough scratch to get out of the garage--no mean feat in the current economic climate--the market may be trying to tell you something.


"You won't really know whether you have a business opportunity until you try to get funding," says Charles Holloway, director of the Center for Entrepreneurial Studies at the Stanford Graduate School of Business.
But don't stop the analysis at the prototype stage. Lasting businesses need a sustainable competitive advantage. What's yours? If it's technology, can you patent it? If it's a commodity item, can you brand it? Sure, you could sell or license your nascent technology and let someone else worry about how to wring profits from it, but is that a bet you want to make?


If you're still convinced you're onto a real business opportunity, ask yourself one last question: How hard are you willing to work? According to the latest data from the Bureau of Labor Statistics, just two-thirds of new businesses make it past the two-year mark, while only 44% last four years--and that's just survival, not success.
Bottom line: If you're not ready to give everything (and then some) to your great idea, it probably won't matter how great Sam smells.

Microsoft's Made A Move On Yahoo!'s Search

The saga between Yahoo! and Microsoft continued on Friday with reports that Microsoft was willing to cough up $1 billion in cash for Yahoo!'s search business.

The reports, which were published on TradeTheNews, said the deal would have raked in an additional $1 billion in operating income for Yahoo! (nasdaq: YHOO - news - people ) annually.

The $1 billion offer was an alternative to a full acquisition and would have allowed Microsoft (nasdaq: MSFT - news - people ) to take control of Yahoo!’s search business.

Another option was for Microsoft to pay $8 billion for a 16.0% stake in Yahoo!, valuing the company at $35 a share.

The unconfirmed report said that Microsoft backed out of the Yahoo! deal because it didn’t believe it could get antitrust approval before the Bush administration left office.

By Yahoo!'s account, the two companies ended nearly five months of negotiations, which included a meeting on June 8 where the software giant "stated unequivocally that [it] is not interested in pursuing an acquisition of all of Yahoo!, even at the price range it had previously suggested," the Sunnyvale, Calif.-based portal said in a statement. (See “ Yahoo! Says ‘It’s Over,’ Microsoft Disagrees”)

That range was $31 to $33 per share. Microsoft launched an unsolicited bid for Yahoo! at $31 per share on Jan. 31 and later raised the offer to $33. Yahoo! wanted at least $37, so Microsoft threw in the towel on May 3.
But Microsoft said the two companies continued to discuss an alternative transaction that Microsoft believed would have delivered more than $33 per share to Yahoo! shareholders.

Meanwhile, Yahoo! said it nixed Microsoft's offer to buy just its search advertising business, saying the transaction “would leave the company without an independent search business that it views as critical to its strategic future and would not be in the best interests of Yahoo! shareholders.”

Yahoo! announced late Thursday an agreement with Google (nasdaq: GOOG - news - people ) that lets the Web portal run ads supplied by Google alongside Yahoo!'s search results and on some of its Web properties in the U.S. and Canada. Yahoo! said the agreement is non-exclusive, giving it the ability to display paid search results from Google, other third parties and Yahoo!'s own search advertising marketplace.

Cordis Turnover Indicator of Stent Collapse

Management problems at Cordis, one of the leading U.S. stent makers, is just further indication that the stent market is not in good health.

The Johnson & Johnson (nyse: JNJ - news - people ) subsidiary has had a round of significant turnover amongst its upper management in recent months with the latest announcement coming Friday morning that Todd Pope, the Cordis group's worldwide president, would leave on July 11.

Pope is said to be leaving to pursue opportunities outside the company and to spend time with his family. A replacement has not yet been named and Cordis said it was not speculating on when Pope's slot would be filled.
Cordis makes medical devices that are used in cardiovascular procedures, particularly drug-eluting stents--small wire-mesh devices that hold the heart arteries open and are covered in therapeutic drugs. There have been signs the stent market is weakening. One of Cordis' major competitors, Boston Scientific, cut jobs at the end of last year, with the Street expecting 2,000 to 3,400 more cuts from its 28,000 employee total.

Pope is the seventh senior person to announce his departure, according to Wachovia (nyse: WB - news - people ) analyst Larry Biegelsen, who broke the news to clients Friday morning.

Other major departures included the company's group chairman, Rick Anderson; chief medical officer, Dr. David Kandzari; vice president of sales, Mark Valentine; vice president of health economics, Brian Firth and his replacement, Liesl Cooper; and the vice president of clinical affairs, Denis Donohoe.

According to Cordis spokesman Chris Allman, the group will continue to be run by current group chairman Seth Fischer, who took over for Anderson in January. He was previously at J&J. Allman added that Donohoe and Firth are both retiring and that Kandzari left to pursue his medical practice.

Biegelsen said in his note that Cordis's products are not performing as well financially as competitors and that this could be an opportunity for some of the group's competitors, specifically Medtronic (nyse: MDT - news - people ), Abbott Laboratories (nyse: ABT - news - people ), and Boston Scientific (nyse: BSX - news - people ), to make further strides.

A recent study showed that Abbott's Xience V stent, when compared with Boston Scientific's Taxus stent, was clinically superior. Biegelsen forecasts that Abbott will have 47% of the market share by 2011. In recent years, the market has been controlled by J&J and Boston Scientific.

A Danish study was published the Journal of the American Medical Association in January comparing the leading stent by Boston Scientific with that from Cordis. The study showed that it made little difference which stent was used and that they performed equally well.

"This is the first large-scale study to address the problem this way," said Dr. Kirk Garratt, clinical director of interventional cardiovascular research at Lenox Hill Hospital in New York City. "They excluded hardly anyone. And in a clinical practice that treats a broad spectrum of patients, it doesn't seem to matter much whether patients get the sirolimus-eluting stent or the paclitaxel-eluting stent."

Health Day News contributed to this article.